Next-generation CRISPR screens to fast-forward drug discovery
Our Technology
At Myllia, we perform functional genomics at scale in advanced cellular models to map the impact of thousands of genetic perturbations at single-cell resolution – a new paradigm to nominate the best possible targets for your drug discovery campaign. Our technology platform enables tailor-made CRISPR screens:
Applications
Pooled CRISPR screens accelerate drug target discovery across many therapeutic areas and help unravel gene regulatory networks in cancer cells and primary human T cells. We utilize CRISPR KO, CRISPRi and CRISPRa technologies combined with multiple high-throughput read-outs for various applications: